Impact of Radioiodine Treatment on Doppler Flow Parameters in the Central Retinal Artery and Ophthalmic Artery in Patients With Hyperthyroidism

The aim of this study was to identify changes in Doppler flow parameters in the central retinal artery (CRA) and ophthalmic artery (OA) that could be indicative of de novo development of thyroid‐associated orbitopathy in the early period after radioiodine treatment.

[1]  M. Mańczak,et al.  A Comparison of Doppler Flow Parameters in the Ophthalmic Artery and Central Retinal Artery in Patients With Graves' Disease and Toxic Nodular Goiter , 2019, Front. Endocrinol..

[2]  Фадеев Валентин Викторович,et al.  Review of American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. , 2017 .

[3]  Guofang Chen,et al.  Interpretation of the 2016 European Thyroid Association/European Group on Graves′ Orbitopathy Guidelines for the management of Graves′ orbitopathy , 2016 .

[4]  S. Rivkees,et al.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. , 2016, Thyroid : official journal of the American Thyroid Association.

[5]  W. Wiersinga,et al.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy , 2016, European Thyroid Journal.

[6]  M. Rola-Pleszczynski,et al.  Impaired immune regulation after radioiodine therapy for Graves’ disease and the protective effect of Methimazole , 2016, Endocrine.

[7]  F. Guillén-Grima,et al.  The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. , 2014, The Journal of clinical endocrinology and metabolism.

[8]  Richard A Armstrong,et al.  Statistical guidelines for the analysis of data obtained from one or both eyes , 2013, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[9]  L. Hegedüs,et al.  Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. , 2012, Endocrine reviews.

[10]  M. Ruchała,et al.  The influence of subclinical hyperthyroidism on blood pressure, heart rate variability, and prevalence of arrhythmias. , 2012, Thyroid : official journal of the American Thyroid Association.

[11]  M. Tsilimbaris,et al.  Choice of analytic approach for eye-specific outcomes: one eye or two? , 2012, American journal of ophthalmology.

[12]  M. Ruchała,et al.  Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism , 2011, Clinical endocrinology.

[13]  A. Avenell,et al.  Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review * , 2008, Clinical endocrinology.

[14]  J. Zachary,et al.  The Risk of Exposure to Diagnostic Ultrasound in Postnatal Subjects , 2008, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[15]  O. Tørring,et al.  TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. , 2008, European journal of endocrinology.

[16]  B. Hekimoğlu,et al.  Graves' Ophthalmopathy: Comparison of the Doppler sonography parameters with the clinical activity score , 2005, Journal of clinical ultrasound : JCU.

[17]  M. Mourits,et al.  Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves' patients. An exploratory study , 2004, Orbit.

[18]  I. Klein,et al.  Thyroid hormone and the cardiovascular system. , 2001, Minerva endocrinologica.

[19]  L. Demers,et al.  Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease , 2003, Clinical endocrinology.

[20]  Z. Baloch,et al.  Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. , 2003, Thyroid : official journal of the American Thyroid Association.

[21]  M. Emoto,et al.  Increased retinal blood flow in patients with Graves' disease: influence of thyroid function and ophthalmopathy. , 2001, European journal of endocrinology.

[22]  İ. Can,et al.  Colour Doppler imaging of the orbital vasculature in Graves' disease with computed tomographic correlation , 2000, The British journal of ophthalmology.

[23]  A. Pinchera,et al.  Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. , 1998, The Journal of clinical endocrinology and metabolism.

[24]  K. Kuma,et al.  Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. , 1996, The Journal of clinical endocrinology and metabolism.

[25]  村上 康弘.  Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome , 1996 .

[26]  C. Gorman,et al.  Diagnostic criteria for Graves' ophthalmopathy. , 1995, American journal of ophthalmology.

[27]  H. Blomgren,et al.  Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? , 1994, European journal of endocrinology.

[28]  K. Mori,et al.  Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine (131I) therapy for hyperthyroid Graves' disease. , 1991, Endocrinologia japonica.